The Board of Directors of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has authorized a buyback plan on September 5, 2022.
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
Equities
RMDA
EGS381B1C015
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.99 EGP | 0.00% | -4.78% | +20.61% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.61% | 63.31M | |
+31.06% | 688B | |
+30.35% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.53% | 239B | |
+10.16% | 210B | |
-8.14% | 200B | |
+8.12% | 167B |
- Stock Market
- Equities
- RMDA Stock
- News Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
- Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. authorizes a buyback plan.